Compare Equinor ASA (EQNR) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs ResMed Inc. — how do they compare? Equinor ASA trades at $35.62 (market cap $82.75B), while ResMed Inc. trades at $202.42 (market cap $28.80B). The key difference: Equinor ASA is far larger — about 2.9× ResMed Inc.'s market cap, and Equinor ASA pays the higher dividend (4.24%). Which is the better fit depends on your goals.
| EQNR | RMD | |
|---|---|---|
Market Cap | $82.75B | $28.80B |
Sector | Energy | Health |
52-Week High | $42.40 | $293.73 |
52-Week Low | $22.41 | $182.82 |
Enterprise Value | $94.51B | $27.99B |
Dividend Yield | 4.24% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EQNR trades at $36.19, up 0.36% on the day, with a bullish technical signal from moving averages. Recent earnings show mixed results, with a Q1 2026 beat but a Q3 2025 miss. The company maintains a strong balance sheet with $21.24B in cash and a low EV/EBITDA of 2.39. Recent news highlights strategic investments in subsea projects and a share buy-back program, reinforcing growth commitments.
The outlook is cautiously optimistic, supported by low valuation metrics and strategic asset expansions. Key risks include volatile energy prices and declining net income margins. Analyst sentiment is mixed, with a 30.43% buy rating, suggesting potential upside but requiring monitoring of execution on production targets.
ResMed (RMD) trades at $196.37, up 1.74% with strong fundamental performance including 27.44% net margins and consistent earnings beats. The company recently sold its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets. Technical indicators show bearish momentum despite oversold RSI conditions, while fundamentals demonstrate robust revenue growth from $5.15B to projected $5.5B in 2026.
RMD presents a compelling growth story with 40% analyst buy ratings and $245.88 consensus target suggesting 25% upside. Key risks include competitive pressures in medical technology and execution of strategic refocusing. The stock's current valuation at 19.15 P/E appears reasonable given earnings momentum and market leadership in sleep apnea treatment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
